Lilly Agrees To Acquire Orna Therapeutics For Up To $2.4Bln In Cash (RNAV)

Lilly (LLY) agreed to acquire Orna Therapeutics in a cash deal valued at up to $2.4 billion, subject to regulatory approvals and the achievement of certain development milestones. The acquisition targets Orna’s RNA-based therapeutics platform, including its lead candidate OR-2001, a potential treatment for rare genetic disorders. The transaction is expected to be completed by the end of 2026, pending closing conditions.